Compare ONCY & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCY | RPTX |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.1M | 92.4M |
| IPO Year | 1999 | 2020 |
| Metric | ONCY | RPTX |
|---|---|---|
| Price | $1.02 | $2.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 683.5K | ★ 751.5K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.89 |
| 52 Week High | $1.51 | $2.30 |
| Indicator | ONCY | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 57.68 |
| Support Level | $0.92 | $2.15 |
| Resistance Level | $1.06 | $2.27 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 77.46 | 43.75 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.